Press release
Prostate Cancer Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Domain | DelveInsight
Stay ahead with the latest insights! Download DelveInsight's comprehensive Prostate Cancer Pipeline Report @ https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight [https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Prostate Cancer Pipeline Report
* On March 02, 2026- Novartis Pharmaceuticals initiated a Phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617) compared with AAA617 (control) in participants with metastatic Castration Resistant Prostate Cancer (mCRPC) with prior exposure to at least 1 Androgen Receptor Pathway Inhibitor (ARPI) and 0-2 taxane regimens and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and pharmacokinetic (PK) data from participants randomized in the study will be evaluated.
* On February 27, 2026- Bayer conducted a phase 3 study is to assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer.
* On February 27, 2026- Merck Sharp & Dohme LLC conducted a Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC).
* On February 24, 2026- Janssen Biotech Inc . announced a phase 2 study is to show that abiraterone acetate plus prednisone added to the current standard of care, gonadotropin-releasing hormone (GnRH) decreases prostate specific antigen (PSA) and prolongs the time until it is evident that the cancer has grown. Additionally, safety information about abiraterone acetate in combination with prednisone will be collected. This will include looking at what side effects occur, how often they occur, and for how long they last.
* DelveInsight's Prostate Cancer pipeline report depicts a robust space with 140+ active players working to develop 150+ pipeline therapies for Prostate Cancer treatment.
* The leading Prostate Cancer Companies such as Janssen Pharmaceutical, POINT Biopharma, Tavanta Therapeutics, Exelixis, Astellas Pharma Inc., Antev, ORCA Therapeutics, Regeneron Pharmaceuticals, Silenseed LTD, Lantheus, Pantarhei Oncology, Zenith Epigenetics, Merck Sharp & Dohme, Bivision Pharmaceuticals, Oncternal Therapeutics, Amunix, FutureChem, Amgen, Taiho Oncology, Harpoon Therapeutics, Arvinas Androgen Receptor Inc., BioNTech SE, Nova Therapeutics, Qilu Pharmaceutical Co., Ltd., Ambrx, Janssen Research & Development, LLC, ORIC Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Clarity Pharmaceuticals Ltd., Vaccitech (UK) Limited, Orion Pharma, Hinova Pharmaceuticals, and Cellbion Co., Ltd., and others.
* Promising Prostate Cancer Pipeline such as Capivasertib, Enzalutamide, Abiraterone, rosuvastatin, digoxin, 18F-PSMA-1007, rhPSMA-7.3 (18F) Injection, and others.
Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Prostate Cancer Treatment Drugs [https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Prostate Cancer Emerging Drugs
* Niraparib: Janssen Research & Development
Niraparib is an orally administered selective poly ADP-ribose polymerase (PARP) inhibitor. In April 2016, Janssen entered a worldwide (except Japan) collaboration and license agreement with TESARO for exclusive rights to niraparib in prostate cancer. In the US, niraparib is indicated for the treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Niraparib is currently marketed as ZEJULA by TESARO, an oncology-focused business within GSK. The drug is currently being evaluated in Phase III clinical trials to treat patients with metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mCSPC).
* ZEN 3694: Zenith Epigenetics
ZEN-3694 is an orally bioavailable, potent, small molecule BET inhibitor that selectively binds to both bromodomains of the BET proteins. The drug candidate was discovered and developed from a BET bromodomain inhibitor platform. Bromodomain and Extra-Terminal domain (BET) family of proteins (BRD2, BRD3, BRD4, and BRDT) can bind acetylated lysines through their tandem bromodomains to promote gene transcription. BET bromodomain inhibitors (BETi) target super enhancers and inhibit several programs involved in tumorigenesis such as proliferation, metastasis, invasion, and immune evasion. The drug is currently being evaluated in the Phase II stage of its development for the treatment of Prostate cancer.
* Ladiratuzumab vedotin: Seagen
Ladiratuzumab vedotin is a novel investigational ADC targeted to LIV-1. Most metastatic breast cancers express LIV-1, which also has been detected in several other cancers, including lung, head and neck, esophageal and gastric. Ladiratuzumab vedotin utilizes Seattle Genetics' proprietary ADC technology and consists of a LIV-1-targeted monoclonal antibody linked to a potent microtubule-disrupting agent, monomethyl auristatin E (MMAE) by a protease-cleavable linker. This novel ADC is designed to bind to LIV-1 on cancer cells and release the cell-killing agent into target cells upon internalization. Ladiratuzumab vedotin may also cause antitumor activity through other mechanisms, including activation of an immune response by induction of immunogenic cell death. Currently, the drug is in the Phase II stage of its development for the treatment of Prostate Cancer.
* FOR46: Fortis Therapeutics
FOR46 is a fully human antibody conjugated to a potent payload, depending on the indication. Fortis Therapeutics is developing FOR46, a novel antibody-drug conjugate (ADC) against CD46, for the treatment of metastatic castration-resistant prostate cancer and late-stage multiple myeloma. The Company is also evaluating additional indications for FOR46. Currently, the drug is in the Phase I/II stage of its development for the treatment of Prostate Cancer.
* REGN5678: Regeneron Pharmaceuticals
REGN5678 is designed to bind to CD28 on cytotoxic T-lymphocytes (CTLs) and PSMA on tumor cells. By binding to the costimulatory T-cell-specific surface glycoprotein and tumor-associated antigen, the drug candidate could activate CTLs and direct them to attack cancer cells. Regeneron identified the targeting of CD28 on previously activated T cells as a way to reduce toxicity compared to CD3 bispecifics. Currently, the drug is in the Phase I/II stage of its development for the treatment of Prostate Cancer.
The Prostate Cancer Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Prostate Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Prostate Cancer treatment.
* Prostate Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Prostate Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Prostate Cancer market.
Explore groundbreaking therapies and clinical trials in the Prostate Cancer Pipeline. Access DelveInsight's detailed report now! @ New Prostate Cancer Drugs [https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Prostate Cancer Companies
Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Blue Earth Diagnostics, Advaxis, Inc., Emtora Biosciences, Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc., Arvinas Inc., Epizyme, Harpoon Therapeutics, Plexxikon, Regeneron Pharmaceuticals, Veru Inc., Jiangsu Hengrui Medicine Co., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Genovax, Cancer Targeted Technology, Bayer, Nymox Pharmaceutical, Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Allife Medical Science and Technology, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio, Inc ., and others.
Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical.
Prostate Cancer Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
Unveil the future of Prostate Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Prostate Cancer Market Drivers and Barriers [https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Prostate Cancer Pipeline Report
* Coverage- Global
* Prostate Cancer Companies- Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Blue Earth Diagnostics, Advaxis, Inc., Emtora Biosciences, Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc., Arvinas Inc., Epizyme, Harpoon Therapeutics, Plexxikon, Regeneron Pharmaceuticals, Veru Inc., Jiangsu Hengrui Medicine Co., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Genovax, Cancer Targeted Technology, Bayer, Nymox Pharmaceutical, Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Allife Medical Science and Technology, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio, Inc ., and others.
* Prostate Cancer Pipeline- Capivasertib, Enzalutamide, Abiraterone, rosuvastatin, digoxin, 18F-PSMA-1007, rhPSMA-7.3 (18F) Injection, and others.
* Prostate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Prostate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Prostate Cancer drug development? Find out in DelveInsight's exclusive Prostate Cancer Pipeline Report-access it now! @ Prostate Cancer Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of contents
* Introduction
* Executive Summary
* Prostate Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Prostate Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Niraparib: Janssen Research & Development
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* ZEN 3694: Zenith Epigenetics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* FOR46: Fortis Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Product Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Prostate Cancer Key Companies
* Prostate Cancer Key Products
* Prostate Cancer- Unmet Needs
* Prostate Cancer- Market Drivers and Barriers
* Prostate Cancer- Future Perspectives and Conclusion
* Prostate Cancer Analyst Views
* Prostate Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=prostate-cancer-clinical-trial-pipeline-appears-robust-with-140-key-pharma-companies-actively-working-in-the-domain-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/prostate-cancer-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Prostate Cancer Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Domain | DelveInsight here
News-ID: 4411674 • Views: …
More Releases from ABNewswire
VendoenCanarias Tops Canary Islands Real Estate Portal Rankings for 2026: Local …
If you're looking to buy or rent property in the Canary Islands, the "best" portal depends on what you value most: local-only inventory, fast owner contact, filters by island/municipality, or sheer volume of listings. This ranking prioritizes practical usefulness for the Canary Islands-especially for people who want to act locally, visit properties quickly, and avoid noise from mainland-focused searches.
1) vendoencanarias.es - Best local-first marketplace for the Canary Islands
https://vendoencanarias.es earns the…
Roofers Service in Lorena - Montgomery Roofing - Lorena Roofers Now Expands Cove …
Montgomery Roofing provides consistent roofers solutions for the Lorena, TX community. As a partner of Nationwide Contracting, the firm utilizes a broad network to ensure projects meet high standards. Nationwide Contracting supports the mission to deliver reliable, safe, and efficient roofing. Local property owners have access to professional support for all property enhancements.
Introduction: Roofers in Lorena, TX
The availability of professional roofers [https://roofstexas.com/lorena-roofers/#:~:text=The%20Premier-,Roofers,-of%20Lorena%2C%20TX] in Lorena, TX, serves as a fundamental utility…
Dr. James B. Joseph Releases New English-Hindi Edition of Victory in Jesus: Bein …
Dr. James B. Joseph announces the release of the fourth English-Hindi edition of Victory in Jesus: Being a Child of God. This bilingual edition expands global access to his foundational Christian teaching, guiding readers toward a personal relationship with God. Rooted in over forty years of ministry and biblical scholarship, the book explores spiritual awakening, obedience, trust, and God's eternal purpose for all people.
Fourth Edition Bridges Spiritual Guidance Across Cultures…
Charissa Ong Ty Didn't Wait for Doors to Open, She Built the House Herself
Malaysian author and independent publisher Charissa Ong Tse Ying breaks into the U.S. market with her 2025 best-selling sci-fi novel Pseudo-Immortals. Founder of Penwings Publishing, she has sold over 60,000 books internationally after overcoming traditional publishing rejection. A PlayStation Malaysia production manager by day, she now expands her literary impact globally with a bold transition from poetry to light science fiction.
Malaysian Author and Publisher Charissa Ong Tse Ying Breaks Into…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
